Mar­ket­ingRx roundup: Pfiz­er leads phar­ma ad wave at Gold­en Globes; Evoke re­brands and stream­lines

Last year
Marketing

Blue­print to pull Gavre­to in cer­tain mar­kets, shelve EGFR pro­grams as it fo­cus­es on Ay­vak­it launch

Last year
R&D

Jen­nifer Doud­na, Fy­o­dor Urnov want to stream­line gene edit­ing stud­ies with Dana­her's help

Last year
R&D
Cell/Gene Tx

Ather­sys files for Chap­ter 11 bank­rupt­cy, sells every­thing to part­ner Healios

Last year
Deals
Cell/Gene Tx

Astel­las hit with CRL for Claudin 18.2 drug due to third-par­ty man­u­fac­tur­ing is­sues

Last year
FDA+
Manufacturing

RTW, Bay­er back Cy­to­ki­net­ics-al­lied Ji Xing Phar­ma­ceu­ti­cals with $162M: #JPM24

Last year
Financing
China

GSK to buy asth­ma biotech Aio­los Bio for up to $1.4B three months af­ter start­up emerged: #JPM24

Last year
Deals
China

Ama­zon launch­es pro­gram to con­nect cus­tomers with dig­i­tal health ben­e­fits: #JPM24

Last year
Health Tech

Ul­tragenyx nears $50M Se­ries A for its Alzheimer's gene ther­a­py spin­out: #JPM24

Last year
Financing
Cell/Gene Tx

#JPM24 quick hits: A 'great year for M&A'; an op­ti­mistic Sarep­ta; Pfiz­er's CEO + more

Last year
Deals
R&D

Pfiz­er CEO says it's back to ba­sics af­ter painful 2023 for in­vestors: #JPM24

Last year
R&D
Pharma

PhRMA read­ies suit over Flori­da's new­ly au­tho­rized Cana­di­an drug im­port plan

Last year
Law

Physi­cians are on board with mR­NA vac­cines, but wor­ry about pa­tient mis­in­for­ma­tion, sur­vey finds

Last year
Pharma
Marketing

Sen­ate health com­mit­tee in­ves­ti­gates in­haler man­u­fac­tur­ers for high prices

Last year
Pharma
FDA+

El­liot­t's Marc Stein­berg sees more health­care in­vest­ments for the some­times-ac­tivist firm this year: #JPM24

Last year
People
Financing

Ver­tex backs out of agree­ment with CRISPR Ther­a­peu­tics for stem cell ther­a­py can­di­date in di­a­betes

Last year
Deals
Pharma

FDA's Pe­ter Marks says some sec­ondary can­cer cas­es af­ter CAR-T ther­a­py may be 'causal,' but ben­e­fits still out­weigh ...

Last year
Cell/Gene Tx
FDA+

Up­dat­ed: No­var­tis close to ac­quir­ing Cy­to­ki­net­ics af­ter biotech's PhI­II heart dis­ease win — WSJ

Last year
Deals

Sen­ti Bio cuts 37% of staff; Evotec pock­ets $25M mile­stone from BMS; No­var­tis buys San­Reno

Last year
News Briefing

Ve­r­a­cyte to buy C2i Ge­nomics for up to $95M, in­cludes $70M up­front

Last year
Deals
Diagnostics

How health tech star­tups sur­vived 2023 de­spite a 4-year fund­ing low

Last year
Health Tech

Ex­elix­is cuts 175 staffers to pri­or­i­tize late-stage drug de­vel­op­ment   

Last year
People
R&D

Bay­er’s $425M non-hor­mon­al ther­a­py for menopause symp­toms clears first PhI­II test

Last year
R&D

Af­fimed cuts up to 50% of em­ploy­ees to sup­port clin­i­cal projects, CEO de­parts

Last year
People
R&D
First page Previous page 220221222223224225226 Next page Last page
A service from the Financial Times